⚠ The Politics of Drug PricesModerate threat

Pharmaceutical pricing power has always depended on a permissive policy environment, above all in the United States, where high drug prices have funded the industry's profits — and that permissiveness is eroding. Drug pricing is now one of the most reliably potent issues in American politics, resented across the spectrum, and the Inflation Reduction Act¹ gave Medicare, for the first time, the power to negotiate prices on selected high-cost drugs. The one market that let drugmakers charge nearly what they wished is beginning to push back.

The danger is structural and one-directional. Everywhere else in the developed world, governments already negotiate hard and pay far less than US payers; as the US moves, however haltingly, in the same direction, the pricing power that underwrites drug economics faces a lasting headwind. For a company like Lilly, whose blockbusters earn their returns on price as much as volume, sustained downward pressure on what it can charge would compress the profitability of the entire patent-protected model.

Lilly's defenses are real: genuinely innovative, high-value drugs retain strong pricing even under negotiation; the obesity and diabetes market is vast enough that volume can offset price; and the political will to truly cut prices often falls short of the rhetoric. But an owner should recognize that the pricing freedom which made pharma so profitable is under real, durable pressure, that the policy direction is unmistakably toward paying less, and that a moat resting partly on high prices is exposed to a politics increasingly hostile to them.